These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18360268)

  • 21. Declining sustained virological response in hepatitis C.
    Batool U; Qureshi S
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):187-91. PubMed ID: 16542597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation.
    Bertuzzo VR; Cescon M; Morelli MC; Di Gioia P; Tamè M; Lorenzini S; Andreone P; Ercolani G; Del Gaudio M; Ravaioli M; Cucchetti A; Dazzi A; D'Errico-Grigioni A; Pinna AD
    Dig Liver Dis; 2012 Oct; 44(10):861-7. PubMed ID: 22819767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
    Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
    J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation.
    Cicinnati VR; Iacob S; Klein CG; Baba HA; Sotiropoulos GC; Hilgard P; Erim Y; Broelsch CE; Gerken G; Beckebaum S
    Aliment Pharmacol Ther; 2007 Jul; 26(2):291-303. PubMed ID: 17593075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of recurrent hepatitis C virus infection after liver transplantation].
    Lengyel G; Tulassay Z
    Orv Hetil; 2007 Oct; 148(40):1875-81. PubMed ID: 17905682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy/prophylaxis with interferon and ribavirin for recurrent hepatitis C after liver transplantation: long-term effects on graft function and morphology.
    Kornberg A; Hommann M; Tannapfel A; Grube T; Schotte U; Scheele J
    Transplant Proc; 2002 Sep; 34(6):2259-60. PubMed ID: 12270389
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.
    Kornberg A; Küpper B; Tannapfel A; Bärthel E; Thrum K; Settmacher U
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2135-42. PubMed ID: 18031371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
    J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
    Merli M; Giannelli V; Gentili F; Giusto M; Simmaco M; Lionetto L; Corradini SG; Biliotti E; Attili AF; Rossi M; Taliani G
    Antivir Ther; 2011; 16(6):879-85. PubMed ID: 21900720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
    Mukherjee S; Lyden E; McCashland TM; Schafer DF
    J Gastroenterol Hepatol; 2005 Feb; 20(2):198-203. PubMed ID: 15683421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha.
    Fischer L; Sterneck M; Valentin-Gamazo C; Feucht HH; Malagó M; Broelsch CE
    Transplant Proc; 1999; 31(1-2):494-5. PubMed ID: 10083207
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.